Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1988 Jan;47(1):43-7.
doi: 10.1136/ard.47.1.43.

Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis

N J McHugh  1 , M Csuka, H Watson, G Belcher, A Amadi, E F Ring, C M Black, P J Maddison
Affiliations
Clinical Trial

Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis

N J McHugh et al. Ann Rheum Dis. 1988 Jan.

Abstract

Iloprost, a stable prostacyclin analogue, was given by intravenous infusion to 29 patients with severe Raynaud's phenomenon, 26 of whom had systemic sclerosis (SS), and compared with placebo infusion in a double blind crossover trial. Iloprost significantly lessened the number and the severity of attacks compared with placebo. Nine patients expressed a preference for effectiveness of treatment, eight of these in favour of Iloprost. Thermography failed to show any long term effect of Iloprost. Side effects of headache, flushing, nausea, and vomiting were common, and the inconvenience of intravenous administration may limit its routine use.

PubMed Disclaimer

References

    1. Br J Clin Pharmacol. 1979 Jul;8(1):7-20 - PubMed
    1. J Int Med Res. 1981;9(6):393-400 - PubMed
    1. Br J Haematol. 1980 Aug;45(4):651-8 - PubMed
    1. Arthritis Rheum. 1980 May;23(5):581-90 - PubMed
    1. Arch Dermatol Res. 1985;277(4):323-5 - PubMed

Publication types